NCT07101159

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Sep 30, 2025
Primary completion: Dec 31, 2031
Completion date: Dec 31, 2031
First posted: Aug 3, 2025
Last posted: Aug 3, 2025
Enrollment: 200
Arms / groups: 2 / —
Source: AACT · ctgov ingestion

Drugs studied

exemestane
dalpiciclib
anastrozole
letrozole
tamoxifen

Indications studied

Breast Neoplasms

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.

NCT07101159

Timeline

Sponsors

Drugs studied

Indications studied